All products are for research use only. Not for human consumption.
Modern longevity research has moved beyond the search for a single anti-aging molecule. Instead, researchers are increasingly interested in compounds that target distinct mechanistic pillars — and how those compounds might complement one another in preclinical models. Three molecules sit at the center of this conversation: Epithalon, NAD+ (and its precursors), and MOTS-c.
This article walks through each compound, the pathway it engages, and the research context in which they are often discussed together. All compounds described are for research use only.
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide composed of Ala-Glu-Asp-Gly. It was developed by Russian researchers led by Vladimir Khavinson, based on a polypeptide originally extracted from the pineal gland.
Epithalon is studied for its proposed effects on telomerase activity. Telomerase is the enzyme responsible for maintaining telomere length — the protective caps at the ends of chromosomes that shorten with each cell division. Preclinical research published in journals including Bulletin of Experimental Biology and Medicine has examined Epithalon's effects on telomere dynamics and cellular senescence markers.
NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme involved in hundreds of cellular reactions. In longevity research, the focus is on its role as a substrate for the sirtuin family of enzymes — particularly SIRT1, SIRT3, and SIRT6 — which regulate gene expression, DNA repair, and metabolic adaptation.
Cellular NAD+ levels decline measurably with age in preclinical models. Sirtuins require NAD+ as a co-substrate, so as NAD+ falls, sirtuin activity falls with it. Research published in Cell Metabolism and related journals has examined NAD+ restoration as a strategy for studying sirtuin-mediated processes in aging models.
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. Its discovery, published in Cell Metabolism in 2015, established the existence of "mitochondrial-derived peptides" as a new class of signaling molecules.
MOTS-c research focuses on its effects on metabolic homeostasis, insulin sensitivity, and mitochondrial function. Unlike Epithalon and NAD+, MOTS-c originates inside the mitochondrion itself and signals outward — it represents a direct line of communication from the organelle to the rest of the cell.
The interesting research question is not which pathway is "best" but how they intersect. Telomere maintenance, sirtuin activation, and mitochondrial signaling are three distinct domains of cellular aging, and they appear largely non-overlapping at the mechanistic level.
This is why investigators studying longevity in preclinical models sometimes describe Epithalon, NAD+, and MOTS-c as three pillars rather than alternatives. A protocol that addresses only one pathway may leave the other two untouched.
In preclinical aging research, multi-compound protocols are common precisely because aging itself is a multi-pathway phenomenon. Researchers designing studies to characterize complementary effects often select one compound from each mechanistic category to ensure broad coverage of the cellular aging landscape.
This is not a recommendation for human use — it is a description of how researchers structure preclinical investigations.
Each of these compounds should meet 98%+ HPLC purity standards with documented Certificate of Analysis. Epithalon and MOTS-c are peptides and follow standard peptide quality protocols. NAD+ and its precursors are not peptides but should still be sourced from suppliers with verifiable purity documentation.
It is important to note that all three compounds remain at the preclinical research stage. Human clinical data are limited or absent, mechanistic claims are based primarily on cell culture and animal models, and translation to human aging biology is not established. All three are sold strictly for laboratory research use only.
Epithalon is studied for telomerase and telomere dynamics, NAD+ for sirtuin activity and DNA repair, and MOTS-c for mitochondrial signaling and metabolic regulation.
In preclinical research, multi-pathway protocols are common because the underlying mechanisms are largely non-overlapping. Researchers designing comprehensive aging studies often select compounds from each category.
No. All three are intended strictly for laboratory research use only. No regulatory approvals exist for these compounds in the longevity context.
Disclaimer: This article is provided for educational and informational purposes only. It does not constitute medical advice. All products referenced are intended strictly for laboratory research use only and are not approved for human consumption.
52 compounds. 99%+ purity. Certificate of Analysis included with every order.